当前位置： SCI文献检索 > Cancer Discovery期刊下所有文献 > HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer.

HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer.

Abstract：

:Primary and acquired resistance to anti-epidermal growth factor receptor (EGFR) drugs are clinically relevant problems in patients with metastatic colorectal carcinoma. A complex network of molecular alterations is involved in this phenomenon. Bertotti et al. report the development of serially transplantable groups of tumor xenografts in immune-deficient mice from patient-derived, genetically characterized metastatic colorectal carcinoma samples. These experimental models ("xenopatients") might represent a novel approach to discover and characterize the mechanisms of resistance to anti-EGFR therapy and other molecularly targeted therapies in metastatic colorectal carcinoma. In this respect, Bertotti et al. were able to identify HER2 gene amplification as one such mechanism of resistance to anti-EGFR therapy.

journal_name

Cancer Discov

journal_title

Cancer discovery

authors

Ciardiello F,Normanno N

doi

10.1158/2159-8290.CD-11-0261

subject

Has Abstract

pub_date

2011-11-01 00:00:00

pages

472-4

issue

6

eissn

2159-8274

issn

2159-8290

pii

1/6/472

journal_volume

1

pub_type

评论,杂志文章

相关文献

Cancer Discovery文献大全
  • Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.

    abstract：:E3 ubiquitin ligases are of interest as drug targets for their ability to regulate protein stability and function. The oncogene Mdm2 is an attractive E3 ligase to target, as it is the key negative regulator of the tumor suppressor p53, which controls the transcription of genes involved in cell fate. Overexpression of ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-11-0104

    authors： Herman AG,Hayano M,Poyurovsky MV,Shimada K,Skouta R,Prives C,Stockwell BR

    更新日期：2011-09-01 00:00:00

  • mTOR inhibition, the second generation: ATP-competitive mTOR inhibitor initiates unexpected receptor tyrosine kinase-driven feedback loop.

    abstract：:mTOR inhibition with the ATP-competitive kinase inhibitor AZD8055 induces receptor tyrosine kinase-dependent feedback activation of AKT. ...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-11-0157

    authors： Keniry M,Parsons R

    更新日期：2011-08-01 00:00:00

  • Antiangiogenic drugs increase xenograft aggressiveness.

    abstract：:Treating human breast cancer xenografts in mice with bevacizumab or sunitinib has increased the population of cancer stem cells found in the tumors. ...

    journal_title：Cancer discovery

    pub_type： 新闻

    doi：10.1158/2159-8290.CD-NB2012-013

    authors：

    更新日期：2012-03-01 00:00:00

  • Patient-derived xenograft models: an emerging platform for translational cancer research.

    abstract：UNLABELLED:Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have ...

    journal_title：Cancer discovery

    pub_type： 杂志文章,评审

    doi：10.1158/2159-8290.CD-14-0001

    authors： Hidalgo M,Amant F,Biankin AV,Budinská E,Byrne AT,Caldas C,Clarke RB,de Jong S,Jonkers J,Mælandsmo GM,Roman-Roman S,Seoane J,Trusolino L,Villanueva A

    更新日期：2014-09-01 00:00:00

  • Hypoxia signaling--license to metastasize.

    abstract：:Hypoxia-inducible factors (HIF) have long been linked to malignant tumor phenotypes in various cancer types, and several downstream mediators of HIF action are deregulated in metastatic carcinomas. A new study links hypoxia-induced collagen remodeling to sarcoma progression, providing evidence for unifying mechanisms ...

    journal_title：Cancer discovery

    pub_type： 评论

    doi：10.1158/2159-8290.CD-13-0481

    authors： Vanharanta S,Massagué J

    更新日期：2013-10-01 00:00:00

  • Global Cost of Smoking Passes $1 Trillion.

    abstract：:A new report from the World Health Organization and the NCI estimates that the worldwide cost of smoking-due to health problems and lost productivity-exceeds $1 trillion annually, with the biggest economic burden falling on low- and middle- income countries. That's because proven interventions, such as tax and price i...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-NB2017-014

    authors：

    更新日期：2017-03-01 00:00:00

  • Durable Responses Achieved with AM0010.

    abstract：:In a phase Ib trial, a combination of the experimental immunotherapy AM0010, a PEGylated form of the recombinant human cytokine IL10, and the anti-PD-1 checkpoint inhibitor pembrolizumab was well tolerated and effective at controlling tumors in some patients with advanced renal cell carcinoma, non-small cell lung canc...

    journal_title：Cancer discovery

    pub_type：

    doi：10.1158/2159-8290.CD-NB2016-125

    authors：

    更新日期：2016-12-01 00:00:00

  • Chemotherapy Efficacy Is Dependent upon p53 Dynamics.

    abstract：:Drug-induced apoptosis occurs after cells reach a p53 threshold level, which increases over time. ...

    journal_title：Cancer discovery

    pub_type： 信件

    doi：10.1158/2159-8290.CD-RW2016-077

    authors：

    更新日期：2016-06-01 00:00:00

  • Cryo-Electron Microscopy Reveals Architecture of the BAF Complex.

    abstract：:The structure of the chromatin-remodeling BAF complex provides molecular-scale mechanistic insight. ...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-RW2020-020

    authors：

    更新日期：2020-03-01 00:00:00

  • Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine.

    abstract：UNLABELLED:The relationships between telomerase and telomeres represent attractive targets for new anticancer agents. Here, we report that the nucleoside analogue 6-thio-2'-deoxyguanosine (6-thio-dG) is recognized by telomerase and is incorporated into de novo-synthesized telomeres. This results in modified telomeres, ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-14-0609

    authors： Mender I,Gryaznov S,Dikmen ZG,Wright WE,Shay JW

    更新日期：2015-01-01 00:00:00

  • Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis.

    abstract：:Epigenetic regulators, when genomically altered, may become driver oncogenes that mediate otherwise unexplained pro-oncogenic changes lacking a clear genetic stimulus, such as activation of the WNT/β-catenin pathway in melanoma. This study identifies previously unrecognized recurrent activating mutations in the G9a hi...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-19-0532

    authors： Kato S,Weng QY,Insco ML,Chen KY,Muralidhar S,Pozniak J,Diaz JMS,Drier Y,Nguyen N,Lo JA,van Rooijen E,Kemeny LV,Zhan Y,Feng Y,Silkworth W,Powell CT,Liau BB,Xiong Y,Jin J,Newton-Bishop J,Zon LI,Bernstein BE,Fish

    更新日期：2020-07-01 00:00:00

  • Mogamulizumab Tops Standard of Care for CTCL.

    abstract：:In the large international phase III MAVORIC trial, patients with previously treated cutaneous T-cell lymphoma who received the anti-CCR4 monoclonal antibody mogamulizumab experienced significantly longer progression-free survival and higher response rates, as well as better quality of life, than those who received vo...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-NB2018-001

    authors：

    更新日期：2018-02-01 00:00:00

  • 53BP1 regulates pRB via a lysine methylation-dependent interaction.

    abstract：:53BP1 integrates pRB activity with the DNA damage response by binding to methylated K810. ...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-RW2014-164

    authors：

    更新日期：2014-09-01 00:00:00

  • BRCA1: a missing link in the Fanconi anemia/BRCA pathway.

    abstract：:Domchek and colleagues provide a case report of a 28-year-old woman with congenital abnormalities, inherited ovarian cancer, and carboplatin hypersensitivity. Interestingly, the woman had validated germline mutations in both BRCA1 alleles. These findings further implicate BRCA1 in the Fanconi anemia/BRCA pathway and h...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-13-0044

    authors： D'Andrea AD

    更新日期：2013-04-01 00:00:00

  • Novel Mitochondrial Mechanisms of Cytarabine Resistance in Primary AML Cells.

    abstract：: Farge and colleagues describe a novel in vivo approach to identify and study primary acute myeloid leukemia (AML) cells that persist in the marrow after chemotherapy. They discovered that AML cells that persist in the mouse marrow after treatment with cytarabine have increased oxidative phosphorylation and that i...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-17-0476

    authors： Schimmer AD

    更新日期：2017-07-01 00:00:00

  • First Comprehensive Companion Diagnostic OK'd.

    abstract：:The FDA has approved F1CDx, a comprehensive companion diagnostic test that can detect genetic alterations and two genomic signatures in any type of solid tumor. Patients with five common types of advanced cancer can be matched to one of 17 targeted therapies with this single test. ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-NB2017-182

    authors：

    更新日期：2018-03-01 00:00:00

  • Resistance emerges to second-generation antiandrogens in prostate cancer.

    abstract：:The appearance of a mutant androgen receptor, AR(F876L), in prostate cancer cells chronically exposed to enzalutamide or ARN-509 promotes a switch from antagonist to agonist receptor function, undermining the potential long-term effectiveness of these second-generation antiandrogen drugs. ...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-13-0405

    authors： Nelson WG,Yegnasubramanian S

    更新日期：2013-09-01 00:00:00

  • BET Proteins as Targets for Anticancer Treatment.

    abstract：:Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that regulate gene expression and are involved in cancer pathogenesis. Over the last years, several BET inhibitors have been developed and clinically tested. Results from the first clinical trials show limited single-agent activity in a small s...

    journal_title：Cancer discovery

    pub_type： 杂志文章,评审

    doi：10.1158/2159-8290.CD-17-0605

    authors： Stathis A,Bertoni F

    更新日期：2018-01-01 00:00:00

  • Exosome Profiling Pinpoints Cancer Type.

    abstract：:A study shows that analyzing the protein contents of exosomes and related extracellular vesicles can distinguish tumors from nearby noncancerous tissue, and profiling extracellular vesicle proteins obtained from plasma may also reveal cancer type. The results support using vesicle proteins for liquid biopsies. ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-NB2020-083

    authors：

    更新日期：2020-11-01 00:00:00

  • ADC Could Benefit Some with Breast Cancer.

    abstract：:Results from a phase I/II trial suggest that an antibody-drug conjugate, sacituzumab govitecan, is active against refractory, metastatic triple-negative breast cancer. A phase III trial is under way to compare its safety and efficacy with that of standard chemotherapy. ...

    journal_title：Cancer discovery

    pub_type： 评论,新闻

    doi：10.1158/2159-8290.CD-NB2019-034

    authors：

    更新日期：2019-05-01 00:00:00

  • A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention.

    abstract：:Immune checkpoint inhibitors (ICI) targeting CTLA-4 or PD-1/PD-L1 have transformed cancer therapy but are associated with immune-related adverse events (irAEs), including myocarditis. Here, we report a robust preclinical mouse model of ICI-associated myocarditis in which mono-allelic loss of Ctla4 in the context of co...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-20-0856

    authors： Wei SC,Meijers WC,Axelrod ML,Anang NAS,Screever EM,Wescott EC,Johnson DB,Whitley E,Lehmann L,Courand PY,Mancuso JJ,Himmel LE,Lebrun-Vignes B,Wleklinski MJ,Knollmann BC,Srinivasan J,Li Y,Atolagbe OT,Rao X,Zhao Y,Wa

    更新日期：2020-11-30 00:00:00

  • Stabilization of a closed kinase conformation induces RAF dimerization.

    abstract：:BRAF inhibitors stabilize a closed, rigid RAF kinase conformation that facilitates dimerization. ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-RW2013-114

    authors：

    更新日期：2013-07-01 00:00:00

  • Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung Cancer.

    abstract：:In the setting of recent exciting clinical results and numerous ongoing trials, Gainor and colleagues explored mechanisms of acquired resistance to first- and second-generation ALK inhibitors in ALK-rearranged non-small cell lung cancer and found that an increased frequency and distinct spectrums of resistance mutatio...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-16-0910

    authors： Qiao H,Lovly CM

    更新日期：2016-10-01 00:00:00

  • Advancing the Precision Medicine Initiative.

    abstract：:The NIH has approved the framework to build a national research cohort of 1 million Americans, a key part of President Obama's Precision Medicine Initiative. ...

    journal_title：Cancer discovery

    pub_type： 新闻

    doi：10.1158/2159-8290.CD-NB2015-146

    authors：

    更新日期：2015-12-01 00:00:00

  • PI3K and STAT3: a new alliance.

    abstract：UNLABELLED:Recent proteomic data have uncovered an interdependence of PI3K and STAT3. In PI3K-tranformed murine cells, STAT3 is phosphorylated on Y705 and activated in a PI3K-dependent manner. Dominant negative STAT3 interferes with PI3K-induced oncogenic transformation. Phosphorylation of STAT3 in PI3K-transformed mur...

    journal_title：Cancer discovery

    pub_type： 杂志文章,评审

    doi：10.1158/2159-8290.CD-11-0218

    authors： Vogt PK,Hart JR

    更新日期：2011-11-01 00:00:00

  • Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.

    abstract：UNLABELLED:Tyrosine kinase domain mutations are a common cause of acquired clinical resistance to tyrosine kinase inhibitors (TKI) used to treat cancer, including the FLT3 inhibitor quizartinib. Mutation of kinase "gatekeeper" residues, which control access to an allosteric pocket adjacent to the ATP-binding site, has ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-15-0060

    authors： Smith CC,Zhang C,Lin KC,Lasater EA,Zhang Y,Massi E,Damon LE,Pendleton M,Bashir A,Sebra R,Perl A,Kasarskis A,Shellooe R,Tsang G,Carias H,Powell B,Burton EA,Matusow B,Zhang J,Spevak W,Ibrahim PN,Le MH,Hsu HH,H

    更新日期：2015-06-01 00:00:00

  • Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.

    abstract：UNLABELLED:Next-generation sequencing was used to identify Notch mutations in a large collection of diverse solid tumors. NOTCH1 and NOTCH2 rearrangements leading to constitutive receptor activation were confined to triple-negative breast cancers (TNBC; 6 of 66 tumors). TNBC cell lines with NOTCH1 rearrangements associ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-13-0830

    authors： Stoeck A,Lejnine S,Truong A,Pan L,Wang H,Zang C,Yuan J,Ware C,MacLean J,Garrett-Engele PW,Kluk M,Laskey J,Haines BB,Moskaluk C,Zawel L,Fawell S,Gilliland G,Zhang T,Kremer BE,Knoechel B,Bernstein BE,Pear WS,Liu

    更新日期：2014-10-01 00:00:00

  • Seeking value as cancer drug costs soar.

    abstract：:As significant increases in the costs of cancer drugs cause financial difficulties for many U.S. patients, some oncologists suggest that changes in pricing policies at the federal and state levels are inevitable. ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-ND2013-018

    authors： Bender E

    更新日期：2013-08-01 00:00:00

  • First CDK 4/6 Inhibitor Heads to Market.

    abstract：:The FDA granted accelerated approval to palbociclib for the treatment of estrogen receptor-positive, HER2-negative metastatic breast cancer in postmenopausal women who have not yet received endocrine-based therapy. Palbociclib is the first cell cycle-targeting CDK 4/6 inhibitor to reach the market. ...

    journal_title：Cancer discovery

    pub_type： 新闻

    doi：10.1158/2159-8290.CD-NB2015-028

    authors：

    更新日期：2015-04-01 00:00:00

  • Molecular dissection of microsatellite instable colorectal cancer.

    abstract：UNLABELLED:Colorectal cancer was one of the first solid tumors to be classified on the basis of molecular profiling. Microsatellite instability has allowed researchers to distinguish a specific subtype of colorectal cancer that has a clearly identified molecular origin (mismatch repair deficiency), arises on a heredita...

    journal_title：Cancer discovery

    pub_type： 杂志文章,评审

    doi：10.1158/2159-8290.CD-12-0471

    authors： Vilar E,Tabernero J

    更新日期：2013-05-01 00:00:00